{
    "ticker": "SMRI",
    "name": "SomaLogic, Inc.",
    "description": "SomaLogic, Inc. is a biotechnology company specializing in proteomics, which is the study of the structure and function of proteins in the body. Founded in 2000, SomaLogic is focused on developing and commercializing its proprietary SomaScan\u00ae platform, a revolutionary technology for measuring the levels of thousands of proteins in a biological sample. This technology enables researchers and clinicians to gain insights into health, disease, and the biological mechanisms underlying various conditions. SomaLogic's mission is to improve human health by harnessing the power of protein biomarker discovery and development. The company collaborates with academic institutions, pharmaceutical companies, and healthcare organizations to apply its technology in various fields, including precision medicine, drug development, and diagnostics. By providing comprehensive proteomic data, SomaLogic aims to empower healthcare professionals to make more informed decisions and tailor treatments to individual patients. The company is committed to advancing the understanding of human biology and improving outcomes for patients through innovative solutions in protein measurement and analysis.",
    "industry": [
        "Biotechnology",
        "Healthcare"
    ],
    "headquarters": "Boulder, Colorado, USA",
    "founded": "2000",
    "website": "https://www.somalogic.com",
    "ceo": "Alfredo J. R. de la Torre",
    "social_media": {
        "twitter": "https://twitter.com/SomaLogic",
        "linkedin": "https://www.linkedin.com/company/somalogic/"
    },
    "investor_relations": "https://investors.somalogic.com",
    "key_executives": [
        {
            "name": "Alfredo J. R. de la Torre",
            "position": "CEO"
        },
        {
            "name": "Michael D. R. Koenig",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Proteomics",
            "products": [
                "SomaScan\u00ae Platform",
                "SomaSignal\u2122 Test"
            ]
        }
    ],
    "seo": {
        "meta_title": "SomaLogic, Inc. | Proteomics and Biomarker Discovery",
        "meta_description": "Explore SomaLogic, Inc., a leader in proteomics with the SomaScan\u00ae platform. Learn about innovative solutions for health and disease insights.",
        "keywords": [
            "SomaLogic",
            "Proteomics",
            "Biomarkers",
            "Precision Medicine",
            "Healthcare Technology"
        ]
    },
    "faq": [
        {
            "question": "What is SomaLogic known for?",
            "answer": "SomaLogic is known for its SomaScan\u00ae platform, which measures thousands of proteins in biological samples."
        },
        {
            "question": "Who is the CEO of SomaLogic?",
            "answer": "Alfredo J. R. de la Torre is the CEO of SomaLogic, Inc."
        },
        {
            "question": "Where is SomaLogic headquartered?",
            "answer": "SomaLogic is headquartered in Boulder, Colorado, USA."
        },
        {
            "question": "What are SomaLogic's main products?",
            "answer": "SomaLogic's main products include the SomaScan\u00ae platform and the SomaSignal\u2122 test."
        },
        {
            "question": "When was SomaLogic founded?",
            "answer": "SomaLogic was founded in 2000."
        }
    ],
    "competitors": [
        "ILMN",
        "EXAS",
        "PACB"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "VRTX"
    ]
}